Personalized Management and Novel Therapies for Neuromuscular Diseases
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".
Deadline for manuscript submissions: closed (15 March 2024) | Viewed by 166
Special Issue Editors
Interests: muscle; myopathy; cardiomyopathy; muscular dystrophy; molecular biology; gene therapy
Special Issue Information
Dear Colleagues,
In conventional medicine, the same diseases are treated with the same drug in different individuals. However, there are individual differences in therapeutic effect and the occurrence of adverse effects depending on the patient’s constitution. Therefore, personalized medicine is attracting attention to provide treatment that suits different patients, even if they have the same disease. In recent personalized medicine, efforts are underway to perform optimal management and treatment tailored to individuals based on the gene mutation of each patient, and the therapeutic agents corresponding to the gene mutation include molecular-targeted drugs and nucleic acid drugs. Personalized medicine has been actively developed not only for cancer and respiratory diseases, but also for neuromuscular diseases. In this Special Issue, we will focus on management or in vitro/in vivo study for the development of treatments in personalized medicine for muscular and cardiomyopathic disorders.
Dr. Akinori Nakamura
Dr. Yoshitsugu Aoki
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- muscle
- myopathy
- cardiomyopathy
- muscular dystrophy
- molecular biology
- model animal
- iPS cells
- molecular therapy
- gene therapy
- stem cell therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
